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Weighted Likelihood Method for Grouped
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Abstract
Grouped failure time data arise often in HIV studies. In a recent preventive HIV
vaccine efficacy trial, immune responses generated by the vaccine were measured
from a case-cohort sample of vaccine recipients, who were subsequently evaluated
for the study endpoint of HIV infection at pre-specified follow-up visits. Gilbert et
al. (2005) and Forthal et al. (2007) analyzed the association between the immune
responses and HIV incidence with a Cox proportional hazards model, treating
the HIV infection diagnosis time as a right censored random variable. The data,
however, are of the form of grouped failure time data with case-cohort covariate
sampling, and we propose an inverse selection probability weighted likelihood
method for fitting the Cox model to these data. The method allows covariates to
be time-dependent, and uses multiple imputation to accommodate covariate data
that are missing at random. We establish asymptotic properties of the proposed
estimators, and present simulation results showing their good finite sample per-
formance. We apply the method to the HIV vaccine trial data, showing that higher
antibody levels are associated with a lower hazard of HIV infection.
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Summary. Grouped failure time data arise often in HIV studies. In a recent preventive
HIV vaccine efficacy trial, immune responses generated by the vaccine were measured from
a case-cohort sample of vaccine recipients, who were subsequently evaluated for the study
endpoint of HIV infection at pre-specified follow-up visits. Gilbert et al. (2005) and Forthal
et al. (2007) analyzed the association between the immune responses and HIV incidence
with a Cox proportional hazards model, treating the HIV infection diagnosis time as a right
censored random variable. The data, however, are of the form of grouped failure time data
with case-cohort covariate sampling, and we propose an inverse selection probability weighted
likelihood method for fitting the Cox model to these data. The method allows covariates
to be time-dependent, and uses multiple imputation to accommodate covariate data that
are missing at random. We establish asymptotic properties of the proposed estimators,
and present simulation results showing their good finite sample performance. We apply the
method to the HIV vaccine trial data, showing that higher antibody levels are associated
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with a lower hazard of HIV infection.
Key Words: Case-cohort design; HIV vaccine trial; Interval censoring; Proportional haz-
ards model; Random dropout; Weighted likelihood.
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1 Introduction
Interval censored data arise when failure times are not exactly observed, but instead the
two time points within which each failure happens are observed. The time points may be,
for instance, the times of clinic visits. Interval censored failure times are commonly seen
in practice, for example patients in clinical trials may be monitored for clinical response at
a set of visit times. A special case of interval censored failure times occurs when the visit
times are fixed in advance and are the same for all subjects. In this case the failure times
are grouped into a discrete set of time intervals. For such a data structure, Kalbfleisch and
Prentice (1973) and Prentice and Gloeckler (1978), among others, proposed and developed
methods for maximum likelihood estimation of the relative risks and survival function in the
proportional hazards model (Cox, 1972; Cox, 1975).
In this article, we consider interval censored survival data with fixed and common visit
times arising from cohort studies with case-cohort sampling of certain covariates of interest.
The case-cohort design was proposed by Prentice (1986) for large cohort studies (e.g., pre-
vention trials) for which the covariates of interest are expensive to collect. In such a design,
the covariate values are collected only for those subjects who experience the failure event
during the follow-up period and for a subcohort that is randomly sampled from the study
cohort. For right censored data, Self and Prentice (1988) derived the asymptotic theory for
a pseudo likelihood estimator of the parameters in a general relative risk model, including
the proportional hazards model as a special case.
Gilbert et al. (2005) employed the Self-Prentice method to analyze data from the first
randomized placebo-controlled Phase 3 trial of a preventive HIV vaccine (Flynn et al., 2005).
Forthal et al. (2007) also analyzed these data, using an alternative psuedo likelihood esti-
mator for the Cox model with case-cohort sampling (Estimator II of Borgan et al., 2000).
These analyses addressed the objective to evaluate in vaccine recipients the association be-
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tween anti-HIV antibody levels generated by the vaccine and subsequent HIV infection. All
volunteers in the trial were immunized with vaccine or placebo at months 0, 1, 6, 12, 18, 24
and 30. Volunteers testing negative for HIV infection at month 0 were enrolled, and HIV
infection tests were administered at each immunization visit and at the final follow-up visit
at month 36. Serum and plasma samples were obtained from all volunteers at the immuniza-
tion visits as well as at visits 2 weeks after the immunization visits, scheduled for measuring
peak immunologic response values. The assays were performed for all vaccine recipients who
became HIV infected and for a stratified random sample of the uninfected vaccine recipients,
selected after the trial.
For study participants who acquired HIV infection during the study, the infection time
can only be determined to be between the dates of the last negative and first positive HIV
tests. In both Gilbert et al.’s (2005) and Forthal et al.’s (2007) Cox model analyses of the
case-cohort data, the time to infection was approximated by the midpoint of the dates of the
last negative and first positive tests. Covariates included the peak immunologic responses
that were measured at 2 weeks after each immunization visit and before the first positive HIV
test (if any), and the demographic variables geographic region, race, and baseline behavioral
risk score (taking integer values from 0 to 7). The peak immunologic response is time-
dependent, but treated as a constant between two adjacent visit times. Approximating
interval censoring to right censoring, however, may introduce bias in parameter estimation.
It is desirable to develop a more general method that takes the interval censoring nature of
the failure times into account.
We propose a weighted likelihood approach to fit a proportional hazards model with
grouped survival data and case-cohort covariate sampling. The method maximizes the in-
verse selection probability weighted log likelihood function (or log partial likelihood function).
The weighted likelihood approach has been used in other missing data problems; see Breslow
2
http://biostats.bepress.com/umichbiostat/paper70
and Wellner (2007) and references cited therein. In our case, the method leads to consistent
and asymptotically normal estimators of the parameters, and the variances of the estimators
are consistently estimated by sandwich variance estimators. The numerical calculations can
be readily carried out via Newton-Raphson iteration. We apply multiple imputation to han-
dle missing immunological responses in the subcohort. We present the proposed methods
and asymptotic results in Section 2 and report a simulation study in Section 3. In Section
4 we apply the proposed method to the vaccine trial example and make concluding remarks
in Section 5. We provide proofs of the asymptotic properties in the Appendix.
2 The Weighted Likelihood Method
Let T be the underlying time to the event of interest, and C be the underlying censoring
time. Let X be a p-dimensional covariate (process). Assume noninformative censoring and
C is independent of T given X. In the HIV vaccine trial study, however, neither T nor C is
completely observed. Instead, T is either known to be in one of the m fixed time intervals:
(t0, t1], (t1, t2], . . . , (tm−1, tm), where 0 = t0 < t1 < . . . < tm−1 < tm = +∞, or right censored
at a visit time tj, 1 ≤ j ≤ m− 1. In either case, X will be observed up to the last observed
visit time. The two cases coincide when j = m− 1.
Suppose we only observe data in the first Ri intervals for subject i, where 1 ≤ Ri ≤ m−1;
then the subject either experiences an event in the Rith interval or is right censored at tRi .
Let ∆ij = 1 if the event for the ith subject falls into the jth interval and ∆ij = 0 otherwise,
1 ≤ j ≤ Ri, and denote ∆i,Ri+1 = 1−
∑Ri
j=1∆ij and ∆i = (∆i1, . . . ,∆i,Ri+1)
′. In fact ∆ij = 0
for all j < Ri, but we keep the vector notation ∆i for ease of technical derivation. Note
that Ri is a random variable and the length of ∆i varies with Ri. Let the covariate be
componentwise constant in each of the m time intervals and denote Xi = (Xi1, . . . , Xim),
whereXij is the p-dimensional covariate vector for the ith subject in the jth interval. Assume
3
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that in a full cohort, we would have n i.i.d. observations (∆i, Ri, Xi), 1 ≤ i ≤ n, which is
equivalent to observing i.i.d. observations (∆i,Ri+1, Ri, Xi), 1 ≤ i ≤ n.
Suppose T follows a Cox regression model, i.e., the hazard function can be written as
λ(t|X(t)) = λ(t) exp(X(t)′β), (1)
where X(t) is the p-dimensional covariate vector at time t and β = (β1, . . . , βp)
′. Let Λ(t)
be the baseline cumulative hazard function, and denote αk = Λ(tk) − Λ(tk−1) and γk =
logαk, k = 1, 2, . . . ,m, where αm and γm are equal to +∞. Then the conditional probability
of the event for the ith subject falling into the jth interval given Xi is
P (∆ij = 1|Xi) = e−
∑j−1
k=1 e
γk+X
′
ikβ
(
1− e−eγj+X
′
ijβ
)
, 1 ≤ j ≤ m.
Here for notational convenience we assume that
∑0
k=1 e
γk+X
′
ikβ = 0. Note that the above
expression only involves covariates observed up to time tj for a fixed j.
Clearly the pair of random variables (∆i, Ri), or equivalently (∆i,Ri+1, Ri), is completely
determined by (Ti, Ci). In particular, the set {∆i,Ri+1 = 0, Ri = j} is equivalent to observing
the event in (tj−1, tj], which in turn is equivalent to the set {Ti ∈ (tj−1, tj], Ci ≥ tj}; and
the set {∆i,Ri+1 = 1, Ri = j} is equivalent to censoring the event at time tj, which in turn
is equivalent to the set {Ti ≥ tj, Ci ∈ (tj−1, tj]}. Let δi denote the realized vector values of
∆i. Then by the conditional independence of Ti and Ci given Xi, the conditional probability
mass function of (∆i, Ri) given Xi can be written as
P (∆i = δi, Ri = j|Xi)
= P
{
Ti ∈ (tj−1, tj], Ci ≥ tj
∣∣∣Xi}1−δi,j+1P{Ti ≥ tj, Ci ∈ (tj−1, tj]∣∣∣Xi}δi,j+1
=
{
e−
∑j−1
k=1 e
γk+X
′
ikβ
(
1− e−eγj+X
′
ijβ
)}1−δi,j+1{
e−
∑j
k=1 e
γk+X
′
ikβ
}δi,j+1
f(δi, j|Xi)
=
j∏
`=1
{
e−
∑`−1
k=1 e
γk+X
′
ikβ
(
1− e−eγ`+X
′
i`β
)}δi`{
e−
∑j
k=1 e
γk+X
′
ikβ
}δi,j+1
f(δi, j|Xi)
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=j+1∏
`=1
(
e−
∑`−1
k=1 e
γk+X
′
ikβ
)δi` (
1− e−eγj+X
′
ijβ
)δij
f(δi, j|Xi)
≡ L(θ|∆i = δi, Ri = j)f(δi, j|Xi), 1 ≤ j ≤ m− 1, (2)
where f(δi, j|Xi) = {P (Ci ≥ tj|Xi)}1−δi,j+1{P (tj < Ci ≤ tj+1|Xi)}δi,j+1 does not contain any
information about θ and hence can be dropped when constructing the likelihood function for
θ. Note that Li(θ) ≡ L(θ|∆i, Ri) above is more complicated than necessary for numerical
evaluation. But its current form will be very helpful in deriving asymptotic properties for
the proposed estimator, which will be easily seen in the Appendix. Also note that Li(θ)
reduces to the likelihood contribution of the ith subject in Prentice and Gloeckler (1978).
In case-cohort studies, the covariates are not observed for all subjects. Here we consider
the Bernoulli sampling scheme (Manski and Lerman, 1977) for selecting the subcohort. Each
subject is examined for a covariate Vi (which can either be part of Xi or be an ancillary
variable(s)) that is measured in all subjects (i.e., at phase one), and is then independently
selected at phase two into the subcohort with probability P (i ∈ SC|Vi) = pi(Vi), where “SC”
stands for subcohort and pi(·) is a known function. The covariate X is assembled only for
subjects in the subcohort and for those who experience the failure event during follow-up.
The data resulting from this sampling scheme preserve an i.i.d. structure and satisfy the
missing at random (MAR) assumption (Little and Rubin, 2002), because the probability
that the covariate X is missing depends only on V and ∆i,Ri+1 , which are always observed.
Kulich and Lin (2004) distinguished between “N-estimation” and “D-estimation” for right
censored data in case-cohort sampling designs, where N-estimation uses weights that are
independent of failure status while D-estimation uses weights that depend on failure status.
The main reason for distinguishing these approaches is that the martingale theory applies for
N-estimation, but not for D-estimation. This distinction is irrelevant for our methodology
for grouped failure time data because it does not have any difficulty in handling failure status
5
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dependent weights.
For the observed data in a case-cohort study, we propose the following weighted likelihood
function for making inferences on θ:
Lw,n(θ) =
n∏
i=1
{
Li(θ)
}wi
, where wi = (1−∆i,Ri+1) +
I(i ∈ SC)
pi(Vi)
∆i,Ri+1, 1 ≤ i ≤ n.
Clearly the weight wi depends on the failure status of subject i. It is easily seen that only
subjects with completely observed covariates contribute to the weighted likelihood function,
and wi is the inverse of the probability that subject i is selected from the original cohort to
have covariate Xi measured. The logarithm of the weighted likelihood function is
`w,n(θ) =
n∑
i=1
wi`i(θ)
=
n∑
i=1
wi
{
−
Ri+1∑
j=1
(
∆ij
j−1∑
k=1
eγk+X
′
ikβ
)
+∆iRi log
(
1− e−e
γRi
+X′iRiβ
)}
. (3)
We call the maximizer of `w,n(θ) the weighted likelihood estimator of θ, denoted by θˆn, which
can be obtained by solving the following weighted log likelihood estimating equation for θ:
∂
∂θ
`w,n(θ) =
n∑
i=1
wi
∂
∂θ
`i(θ) = 0. (4)
The Newton-Raphson method can be employed to solve the above estimating equation.
Denote hij = e
γj+X
′
ijβ, 1 ≤ i ≤ n, 1 ≤ j ≤ m− 1. The first order derivatives of the weighted
likelihood function are ∂`w,n(θ)/∂θ =
∑n
i=1wi∂`i(θ)/∂θ, where
∂`i(θ)
∂β
= −
Ri+1∑
j=1
(
∆ij
j−1∑
k=1
hikXik
)
+∆iRi
hiRie
−hiRi
1− e−hiRiXiRi ,
∂`i(θ)
∂γs
= −
Ri+1∑
j=s+1
{∆ijhisI(Ri ≥ s)}+∆is hise
−his
1− e−his I(Ri = s), 1 ≤ s ≤ m− 1. (5)
Let
bij =
hije
−hij
1− e−hij
(
1− hij
1− e−hij
)
, 1 ≤ i ≤ n, 1 ≤ j ≤ m− 1.
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Then the second order derivatives are ∂2`w,n(θ)/∂θ∂θ
′ =
∑n
i=1wi∂
2`i(θ)/∂θ∂θ
′, where
∂2`i(θ)
∂β∂β′
= −
Ri+1∑
j=1
(
∆ij
j−1∑
k=1
hikXikX
′
ik
)
+∆iRibiRiXiRiX
′
iRi
,
∂2`i(θ)
∂γ2s
= −
Ri+1∑
j=s+1
{∆ijhisI(Ri ≥ s)}+∆isbisI(Ri = s), 1 ≤ s ≤ m− 1,
∂2`i(θ)
∂β∂γs
= −
Ri+1∑
j=s+1
{∆ijhisXisI(Ri ≥ s)}+∆isbisXisI(Ri = s),
∂2`w,n(θ)
∂γs∂γt
= 0, s 6= t.
Note that the covariates after theRith interval do not contribute to the log likelihood function
and its derivatives. Define the matrix of the second derivatives as
In =
(
Iγγ,n Iγβ,n
I ′γβ,n Iββ,n
)
=
( −∂2`w,n(θ)/∂γ∂γ′ −∂2`w,n(θ)/∂γ∂β′
−∂2`w,n(θ)/∂β∂γ′ −∂2`w,n(θ)/∂β∂β′
)
.
The numerical inversion of In is necessary in Newton-Raphson iteration, which may be
difficult if there are many intervals (m is large). Following the idea of Prentice and Gloeckler
(1978) and Finkelstein (1986), however, the inversion can be simplified by using the following
equality
I−1n =
(
I−1γγ,n + AB
−1A′ −AB−1
−B−1A′ B−1
)
,
where A = I−1γγ,nIγβ,n, B = Iββ,n − I ′γβ,nI−1γγ,nIγβ,n, which only involves inverting the p-
dimensional matrix B since Iγγ,n is diagonal. Then the Newton-Raphson method updates
values of θ = (γ′, β′)′ iteratively via(
γ(k)
β(k)
)
=
(
γ(k−1)
β(k−1)
)
+
{
I−1n
∂`w,n(θ)
∂θ
}
θ=θ(k−1)
until the algorithm converges; here the superscript (k) represents values in the kth iteration.
Note that when the sample size is small, or some time intervals are narrow, there may be
7
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no observed events in an interval, in which case the Newton-Raphson procedure will fail. A
simple remedy is to combine such an interval with its neighbor to make the number of events
in the combined interval greater than 0.
The dependency of the sampling probabilities on covariates and outcome makes the case-
cohort design a biased sampling design. The inverse selection probability weighted estimating
equation (4) corrects the bias, however, because by MAR we have
E(wi|∆i, Ri, Xi, Vi) = (1−∆i,Ri+1) + ∆i,Ri+1
P (i ∈ SC|Vi)
pi(Vi)
= 1, (6)
and hence
E
{
wi
∂`i(θ)
∂θ
}
= EE
{
wi
∂`i(θ)
∂θ
∣∣∣∣∆i, Ri, Xi, Vi}
= E
{
∂`i(θ)
∂θ
E(wi|∆i, Ri, Xi, Vi)
}
= E
{
∂`i(θ)
∂θ
}
= 0. (7)
A naive approach to the analysis would simply put wi = 1 for all subjects with covariates
completely observed and wi = 0 otherwise. We call the corresponding estimator the naive
estimator. Since the equality (6) does not hold for all i, in general the naive estimator will
be asymptotically biased, which is verified by the simulation study in Section 3.
For full cohort data, Prentice and Gloeckler (1978) provided an intuitive discussion on the
asymptotic properties of the maximum likelihood estimator for grouped survival data. We
give a set of mild regularity conditions in the following theorem that formally establishes both
consistency and asymptotic normality of the weighted likelihood estimator, which includes
the maximum likelihood estimator of Prentice and Gloeckler (1978) as a special case. The
proof is deferred to the Appendix.
Theorem 1: Suppose the parameter space Θ is compact and the true parameter θ0 is
an interior point of Θ. Assume the following conditions hold:
8
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(i) The covariate X has bounded support.
(ii) The variance matrix of Xij is positive definite for all 1 ≤ j ≤ m− 1.
(iii) pi(Vi) ≥ δ > 0 for all i and some δ > 0.
(iv) P (Ci ≥ tm−1|Xi) > 0 with probability 1.
If the maximizer θˆn of `w,n(θ) does not occur on the boundary of Θ, then as n → ∞,
θˆn converges to θ0 in probability, and
√
n(θˆn − θ0) converges in distribution to a Gaussian
random variable with mean zero and variance Σ(θ0) = I
−1(θ0)D(θ0)I−1(θ0), where I(θ) =
Eθ0{∂2`i(θ)/∂θ∂θ′} and D(θ) = Eθ0 [{wi∂`i(θ)/∂θ}{wi∂`i(θ)/∂θ}′].
Note that the compactness of Θ and the boundedness of X guarantee that the probability
of observing an event in each of the m intervals is strictly bounded between 0 and 1.
The asymptotic variance Σ(θ0) can be consistently estimated by the sandwich estimator
Σˆn(θˆn) = Iˆ
−1
n (θˆn)Dˆn(θˆn)Iˆ
−1
n (θˆn), (8)
where Iˆn(θ) = n
−1∑n
i=1wi{∂2`i(θ)/∂θ∂θ′}, Dˆn(θ) = n−1
∑n
i=1w
2
i {∂`i(θ)/∂θ}{∂`i(θ)/∂θ}′.
3 Simulation Study
We conducted simulations to assess the performance of the weighted likelihood estimator by
comparing the bias, efficiency and coverage properties to other estimators including the max-
imum likelihood estimator for full cohort data, the naive estimator for case-cohort data, and
the Self-Prentice (1988) pseudo likelihood estimator for case-cohort data. The pseudo like-
lihood estimation is based on approximating interval censoring by right censoring, whereby
event times are defined by the midpoint of the left- and right-censoring intervals.
We consider two covariates (X1, X2), where the corresponding coefficients are (1,−1)′.
Note that the subscript of X here denotes covariate component, not an index for study
subject as in Section 2. To match the HIV vaccine trial (Flynn et al., 2005), we set the time
9
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origin as 6.5 months post-entry (the time by which the study subjects are “fully immunized”)
and use six time intervals (m = 6) with fixed visit times at months 12, 18, 24, 30, and 36. The
covariateX1 is set to be discrete and time-independent, which takes values 1 and 2 with equal
probability. The covariate X2 = (X21, X22, X23, X24, X25)
′ is specified as a 5-variate random
vector corresponding to the five post-immunization visits at months 6.5, 12.5, 18.5, 24.5, 30.5,
where X2j is the covariate value of X2 in the jth interval. The conditional distribution of X2
given X1 is normal, i.e., X2|X1 = k ∼ N(µk,Σ), k = 1, 2, with µ1 = (0.1, 0.2, 0.3, 0.4, 0.5)′,
µ2 = (0, 0.1, 0.2, 0.3, 0.4)
′, and
Σ =

1 ρ ρ2 ρ3 ρ4
ρ 1 ρ ρ2 ρ3
ρ2 ρ 1 ρ ρ2
ρ3 ρ2 ρ 1 ρ
ρ4 ρ3 ρ2 ρ 1
 ,
where ρ = 0.7. With this set-up the covariates X2j, j = 1, . . . , 5, are positively correlated
following an AR(1) model, and X1 and X2 are also correlated.
We choose the cohort size n as 500 or 3000. When n = 500, the probability of selecting
censored subjects into the subcohort is 0.25 and the baseline hazard is a constant value
0.02; when n = 3000, the selection probability is 0.085 for censored subjects and the baseline
hazard is a constant value 0.005. With these settings there are approximately 200 completely
observed subjects when n = 500, among whom about half are failures, and approximately
400 completely observed subjects when n = 3000, among whom about 150 are failures.
The latter situation resembles the HIV vaccine trial data that will be analyzed in the next
section. The survival times are generated from a piecewise exponential distribution specified
by model (1) (with λ0(t) ≡ c specified above). Censoring times are generated from a discrete
uniform subdistribution at months (12, 18, 24, 30) combined with a truncation at month 36
to yield about 25 early dropouts (prior month 36), similar to what was observed in the HIV
study. One thousand simulation runs are conducted under each simulation setting.
10
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For each simulation run, parameter estimates are obtained by solving equation (4) using
the Newton-Raphson method. The initial value of β is set to be zero, and the initial value
of γ is obtained from the Kaplan-Meier curve S(0)(·), calculated by pushing the failure time
to the right end point of the interval in which an event occurs, via γ
(0)
j = log[log{S(0)(tj)}−
log{S(0)(tj+1)}], 1 ≤ j ≤ m − 1. Then the variance estimator is calculated from (8), and
the 95% Wald confidence interval for each parameter is obtained based on the asymptotic
normality. Bias, coverage percentage, the average of the estimated standard deviations, and
the empirical standard deviation are calculated from the 1000 simulation runs. Since the
parameter of interest is β, only the bias for estimating γ is reported. The relative efficiency
of the weighted likelihood estimator of β versus the maximum likelihood estimator (MLE)
computed from the full data is calculated by the ratio of empirical variances.
Due to the expense of measuring the antibody responses in the HIV vaccine trial, the
antibody level for vaccine recipients who failed was only measured at the beginning of the
first interval (at the month 6.5 visit) and at the visit immediately preceding the failure visit,
and for censored vaccine recipients it was only measured at month 6.5 and at a randomly
selected visit month after month 6.5. Since the missing elements of X for subject i are
missing by design, depending only on ∆i,Ri+1 , the missing mechanism is MAR (Little and
Rubin, 2002). To handle this type of missing data, we propose using multiple imputation to
fill in the missing components of X.
Specifically, suppose only X2 can be missing. For each time interval 2 through 5 (exclud-
ing the last interval), we impute the missing values of X2 by random draws from a linear
regression model with the covariate in the first interval as the predictor, which is fitted sepa-
rately for cases and non-cases. For example, to impute missing covariate values in the second
interval for cases, we first fit a linear model X22 = c0 + c1X21 + ε, where ε ∼ N(0, σ2), using
all the cases with complete data for X22. After obtaining estimates cˆ = (cˆ0, cˆ1)
′ and σˆ2, we
11
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then take a random draw of σ∗2 from σˆ2χn+1, where n is the number of subjects included in
the linear regression, and c∗ and ε∗ are random draws from N(cˆ, σ∗2(A′A)−1) and N(0, σ∗2),
respectively, where A is the design matrix of the linear regression. Finally, we fill in the
missing value X22 by Xˆ22 = c
∗
1 + c
∗
2X21 + ε
∗. We construct 10 complete data sets following
this procedure. For each imputed data set, we calculate the weighted likelihood estimator
of β and its variance estimate, and then combine the 10 sets of results using the method of
Little and Rubin (2002) to obtain the final estimate and its variance estimate. Confidence
intervals for β are calculated using the t distribution following Little and Rubin (2002).
In addition to evaluating the different methods with no missing components in X, we
evaluate the weighted likelihood method with multiple imputation, by coarsening the sim-
ulated X2 covariates to have missing components in the pattern described above. Tables 1
and 2 summarize the simulation results. From Table 1 we see that the weighted likelihood
estimators have reasonably small biases. The standard deviation estimators for βˆ are accu-
rate, which lead to accurate coverage percentages. The multiple imputation method works
well. It is not surprising that the weighted likelihood method for case-cohort data is less
efficient than the maximum likelihood estimator for the full cohort data. However, under
case-cohort sampling the weighted likelihood method is much more efficient than the naive
method that uses simple random sampling. In addition, by ignoring the biased sampling
nature of the case-cohort sampled data, the naive estimator is clearly biased. The pseudo
likelihood method of Self and Prentice (1988) that uses approximated right censored data is
also more biased than the weighted likelihood method for grouped survival data. From Table
2 we see that the bias of γˆ is severe for both the naive method and the pseudo likelihood
method, whereas it is very small for the weighted likelihood method.
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4 Analysis of the HIV Vaccine Trial Data
We now analyze the HIV vaccine trial data using the weighted likelihood method to investi-
gate the association between antibody levels and HIV infection. Subjects randomly assigned
to the vaccine group received innoculations at months 0, 1, 6, 12, 18, 24 and 30, and plasma
and serum samples were obtained at the “peak antibody response” study visits at months
0.5, 1.5, 6.5, 12.5, 18.5, 24.5 and 30.5. Gilbert et al. (2005) and Forthal et al. (2007) stud-
ied many types of antibody measurements in the trial. We investigate the newest antibody
measurement described in Forthal et al. (2007), which quantitates the degree to which the
serum of a vaccine recipient reduces (relative to control serum) the avidity of the binding
of soluble CD4 to the GNE8 strain of HIV. We refer to this antibody variable as the GNE8
CD4 avidity level. We focus on measurements taken at month 6.5, 12.5, 18.5, 24.5, and 30.5
to evaluate the relationship between peak GNE8 CD4 avidity levels and the rate of HIV
infection. Because this antibody variable was only obtained from vaccine recipients who
tested HIV negative at month 6, and the main scientific goal is to evaluate the association in
vaccine recipients after they received the third immunization at month 6.5, the time intervals
for analysis are [6.5, 12), [12.5, 18), [18, 24), [24, 30), [30, 36), and [36,∞), where month 36
is the time of the final study visit.
The GNE8 CD4 avidity level is measured for all infected vaccine recipients and for a
stratified random sample of uninfected vaccine recipients. Placebo recipients are not used in
the analysis because their GNE8 CD4 avidity levels all equal 0. The stratification variable is
defined by five demographic subgroups: white low risk men, nonwhite low risk men, low risk
women, white higher risk men, and nonwhite higher risk men, with sampling probabilities
0.05, 0.18, 0.03, 0.20, and 0.45, respectively. Here low (higher) risk subjects are those who
had baseline behavioral risk score (defined in Flynn et al., 2005) below or equal to (greater
than) 2. The entire cohort size of vaccine recipients at the time origin month 6.5 is 3330, of
13
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whom 131 became HIV infected by month 36. The numbers of uninfected vaccine recipients
who were sampled for measuring the GNE8 CD4 avidity level were 113, 69, 66, 25, and 4
for the five strata. Among the 277 sampled uninfected vaccine recipients, 254 were right
censored at month 36, and 23 subjects were right censored at an earlier visit time.
In addition to the primary covariate of interest peak GNE8 CD4 avidity level, other
covariates included in the Cox model analysis are race (white or nonwhite), sex (male or
female) and baseline behavioral risk score. The baseline risk score is categorized into three
groups: low (< 2), medium (2 or 3), and high (> 3). The peak antibody level is time-
dependent, but is assumed constant between two adjacent vaccine shots. Everyone in the
case-cohort data set has the peak antibody level measured in the first time interval (at
6.5 months). For every infected subject, the antibody level is also measured in the time
interval in which the infection occurs, while for every uninfected subject, the antibody level
is measured in a randomly selected time interval in addition to the first time interval. The
antibody levels in all other time intervals are missing by design, and hence are MAR.
To handle the missing covariate data, we use the same approach described in Section
3, wherein 10 complete data sets are created by repeatedly imputing all missing antibody
values, the weighted likelihood method is applied to each complete data set, and Little and
Rubin’s (2002) technique is used to compute the final regression parameter estimates and
their associated standard deviations and confidence intervals. During the data exploration we
found that the contribution of the antibody level in model (1) is monotone, but not linear,
with faster increase at lower antibody levels. By trying out a few power transformations
of the antibody level, we found the one fifth power transformation seemed to provide an
estimated linear effect. Hence we implemented this transformation in the final analysis.
The results are presented in Table 3. We first investigated interactions between antibody
level and the other covariates, and none are statistically significant. On main effects, race
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and sex effects are not statistically significant, while baseline risk group is highly significant.
Compared to the low risk group, the estimated relative hazard of HIV infection for the
medium or high risk groups is approximately tripled, controlling for antibody level, race
and gender. The GNE8 CD4 avidity levels are significantly inversely associated with HIV
infection rate. Note that on their original scale the antibody levels range from 0 to about
0.75, and their transformed values range from 0 to about 0.95. From Table 3 we see that the
estimated log relative hazard of infection for every 0.1 unit increase in the one fifth power
of antibody level is −0.156 with 95% confidence interval of (−0.235,−0.076), controlling for
race, gender and baseline risk score. Transformed back to the original scale, the strength of
association is larger at lower values of the antibody level. For example, an antibody level of
0.25 compared to 0 reduces the hazard of HIV infection by about 69.2%; an antibody level of
0.5 compared to 0.25 reduces the hazard by 16.1%; and the antibody level of 0.75 compared
to 0.5 reduces the hazard by 10.8%, controlling for race, gender and baseline risk score.
5 Discussion
The case-cohort sampling considered here is independent Bernoulli sampling that yields ran-
dom sample sizes. The advantage of this sampling scheme is the resulting i.i.d. structure
of the data, which leads to parameter estimators with more manageable asymptotic proper-
ties. An alternative approach would be sampling without replacement, wherein the number
of sampled subjects is fixed. A different proof of the large sample properties needs to be
developed for the non-i.i.d. sampling method. The method of Breslow and Wellner (2007)
may apply.
It should also be noted that, although the weighted likelihood estimator provides an in-
tuitively reasonable method that can be easily carried out numerically, it is not the most
efficient estimator. Efficient estimation will in general involve the joint distribution of co-
15
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variates and high-dimensional integration, and hence is much more complicated, especially
when some covariates are continuous. When covariates are discrete, a simpler derivation is
possible, but not pursued here.
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Appendix: Proof of Theorem 1
The proof of consistency of θˆn is based on Theorem 5.7 of van der Vaart (1998), which can
be reduced to the following Lemma 1 that is more relevant to our problem. In the following
we omit the word “outer” from outer probability and outer integral, and refer the detailed
arguments to van der Vaart and Wellner (1996), Chapter 1.
18
http://biostats.bepress.com/umichbiostat/paper70
Lemma 1: For i.i.d. observations Z1, · · · , Zn, let Mn(θ) = n−1
∑n
i=1mθ(Zi) and M(θ) =
Emθ(Z), where θ ∈ Θ ⊂ Rd. Assume that Θ is compact, M(θ) is continuous and has a
unique maximizer at θ0, and the measurable function θ 7→ mθ(Z) is continuous for every
Z and dominated by an integrable function. Then any sequence of estimators θˆn satisfying
Mn(θˆn) ≥Mn(θ0)− oP (1) converges in probability to θ0 as n→∞.
Proof: Since Θ is compact and the function θ 7→ mθ(Z) is continuous for every Z
and dominated by an integrable function, the class of functions {mθ : θ ∈ Θ} is Glivenko-
Cantelli (see example 19.8 in van der Vaart, 1998). Hence we have the uniform convergence
of Mn(θ), i.e., supθ∈Θ |Mn(θ)−M(θ)| → 0 in probability as n→∞. On the other hand, by
the compactness of Θ and the fact that the function M(θ) has a unique maximizer at θ0, we
have sup‖θ−θ0‖≥εM(θ) < M(θ0) for every ε > 0. Hence the conditions of Theorem 5.7 of van
der Vaart (1998) are satisfied, and it follows that θˆn → θ0 in probability.
We now apply Lemma 1 to prove the consistency of θˆn in Theorem 1. By Lemma 1, it
suffices to show that the class of functions {w`(θ) : θ ∈ Θ} are continuous and bounded by
an integrable function, and µ(θ) = Eθ0{w`(θ)} is continuous and has a unique maximizer at
θ0, where `(θ) is the log likelihood function for one subject with the subscript i suppressed.
From (3) we see that `(θ) is continuous and bounded by a constant since γ, β and Xj are
all bounded. In addition, w is bounded by Condition (iii). Thus the function θ 7→ w`(θ) is
uniformly bounded by an integrable function. Then the continuity of µ(θ) follows from the
dominated convergence theorem. It remains to show that µ(θ) has a unique maximizer at
θ0.
Let µ∗(θ) = µ(θ)−µ(θ0). Denote the joint density of (∆, r,X) by pθ. Then for any θ ∈ Θ
we have
µ∗(θ) = Eθ0{w`(θ)− w`(θ0)}
19
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= Eθ0
{
w log
pθ(∆, r,X)
pθ0(∆, r,X)
}
= Eθ0
{
log
pθ(∆, r,X)
pθ0(∆, r,X)
Eθ0(w|∆, r,X, V )
}
= Eθ0
{
log
pθ(∆, r,X)
pθ0(∆, r,X)
}
by (6)
≤ logEθ0
{
pθ(∆, r,X)
pθ0(∆, r,X)
}
by the Jensen’s inequality (9)
= log 1 = 0.
Hence µ(θ) is maximized at θ0. Note that the above calculation shows that µ
∗(θ) is equivalent
to the negative Kullback-Leibler divergence and thus less than or equal to 0. Furthermore,
since the equality in (9) holds if and only if pθ0(∆, r,X) = pθ(∆, r,X) with probability 1, we
have that µ(θ) = µ(θ0) if and only if pθ0(∆, r,X) = pθ(∆, r,X) with probability 1. Denote
θ0 = (γ1,0, · · · , γm−1,0, β′0)′. Then by (2) we have γk + X ′kβ = γk,0 + X ′kβ0, or equivalently
X ′k(β−β0) = γk,0−γk, with probability 1, for all k. Since Var(Xk) > 0, we must have β = β0
and γk = γk,0 for all k, i.e., θ = θ0. Therefore, µ(θ) has a unique maximizer at θ0. Thus the
consistency of θˆn follows from Lemma 1.
The proof of asymptotic normality of θˆn in Theorem 1 can be done by applying Theorem
5.23 of van der Vaart (1998), which is listed as Lemma 2 in the following for ease of reference.
Lemma 2: Let Z1, . . . , Zn be a random sample from some distribution P . For each θ
in an open subset of Euclidean space, let z 7→ mθ(z) be a measurable function such that
θ 7→ mθ(z) is differentiable at θ0 for P−almost every z with derivative m˙θ0(z) and such that,
for every θ1 and θ2 in a neighborhood of θ0 and a measurable function m˙ with EP m˙
2 <∞,
|mθ1(z)−mθ2(z)| ≤ m˙(z)‖θ1 − θ2‖.
Furthermore, assume that the map θ 7→ EPmθ admits a second order Taylor expansion
at a point of maximum θ0 with nonsingular symmetric second derivative matrix Vθ0 . If
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∑n
i=1mθˆn(Zi) ≥ supθ
∑n
i=1mθ(Zi)− op(1) and θˆn →P θ0, then
√
n(θˆn − θ0) = −V −1θ0
1√
n
n∑
i=1
m˙θ0(Zi) + oP (1).
Proof: See van der Vaart (1998), page 54.
We introduce some additional notation before proving the asymptotic normality of θˆn.
We still suppress the subscript i for subject i because we have i.i.d. observations. For a
single observation, let D = 1 if the subject either has a failure observed or is right censored
at tm−1 (the last visit time), and D = 0 if the subject is right censored at a time earlier than
tm−1. We also extend the length of ∆ to m if an event is observed (it is m when the failure
time is censored at tm−1) by adding m− r zeros to the remaining intervals after the interval
thaqt contains the event. Then the likelihood function for the subject can be decomposed
as
L(θ) =
[
m∏
j=1
{
e−
∑j−1
k=1 e
γk+X
′
kβ
(
1− e−eγj+X
′
jβ
)}∆j]D {
e−
∑r
j=1 e
γj+X
′
jβ
}1−D
≡ {L(1)(θ)}D{L(2)(θ)}1−D.
Likewise, the log likelihood function can be written as
`(θ) = D`(1)(θ) + (1−D)`(2)(θ), (10)
where `(1)(θ) = logL(1)(θ), and `(2)(θ) = logL(2)(θ).
We are now in a position to prove the asymptotic normality of θˆn by checking the condi-
tions of Lemma 2. Identify Z and mθ(Z) in the lemma with (∆, r,X) and w`(θ). Obviously
the map z 7→ mθ(z) is measurable and θ 7→ mθ(z) is differentiable at any θ in Θ for every
z. By (5) and the boundedness of w, θ and (∆, r,X), every element of m˙θ(z) = ∂mθ(z)/∂θ
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is bounded in both θ and z by a common constant, say, C. By the mean value theorem and
the Cauchy-Schwartz inequality we have
|mθ1(z)−mθ2(z)| = |m˙θ∗(z)′(θ1 − θ2)| ≤ ‖m˙θ∗(z)‖ · ‖θ1 − θ2‖ ≤ (p+m− 1)C‖θ1 − θ2‖,
where θ∗ lies on the line segment between θ1 and θ2. Hence we can take m˙(z) in Lemma
2 to be (m + p − 1)C and the condition EP m˙2(Z) < ∞ is automatically satisfied. Since
elements in both ∂mθ(z)/∂θ and ∂
2mθ(z)/∂θ∂θ
′ are bounded by integrable functions, by
the dominated convergence theorem we can exchange the second order derivative and the
expectation. Hence the map θ 7→ EPmθ admits a second-order Taylor expansion. Now we
only need to show that Vθ0 in Lemma 2 is nonsingular.
By (6) we have EPmθ = EP{w`(θ)} = EP `(θ). Hence Vθ0 = EP{∂2`(θ)/∂θ∂θ′} = −I(θ0).
Since
I(θ0) = −EP
{
∂2`(θ)
∂θ∂θ′
}
θ=θ0
= EP
{
∂`(θ)
∂θ
(
∂`(θ)
∂θ
)′}
θ=θ0
,
if I(θ0) singular, then there must exist a nonzero constant real vector α such that α
′I(θ0)α =
0, which implies by (10) that
EP
{
α′
∂`(θ)
∂θ
}2
θ=θ0
= EP
{
D
(
α′
∂`(1)(θ)
∂θ
)2
+ (1−D)
(
α′
∂`(2)(θ)
∂θ
)2}
θ=θ0
= 0.
Hence EP [D{α′∂`(1)(θ)/∂θ}2]θ=θ0 = 0. Again by (10) we have,
∂`(1)(θ)
∂γs
∣∣∣∣
θ=θ0
= −
m∑
j=s+1
∆jh
0
s +∆s
h0se
−h0s
1− e−h0s , s = 1, 2, · · · ,m− 1,
∂`(1)(θ)
∂β
∣∣∣∣
θ=θ0
=
m∑
j=1
∆j
(
−
j−1∑
k=1
h0kXk +
h0je
−h0j
1− e−h0j
Xj
)
,
where h0s = e
γs+X′sβs|θ=θ0 , 1 ≤ s ≤ m− 1. Hence we have
EP
{
D
(
α′
∂`(1)(θ)
∂θ
)2}
θ=θ0
= EP
{
m∑
j=1
D∆jfj(X)
}2
θ=θ0
= EP
{
m∑
j=1
D∆jf
2
j (X)
}
θ=θ0
=
m∑
j=1
EP
{
P (∆j = D = 1|X)f 2j (X)
}
= 0 (11)
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for some function fj. Now by (2), (10) and Assumption (iv), we obtain
P (∆j = D = 1|X) = e−
∑j−1
k=1 h
0
k
(
1− e−h0j
)
P (C ≥ tj|X) > 0, j < m,
and
P (∆m = D = 1|X) = e−
∑j−1
k=1 h
0
k
(
1− e−h0j
)
P (C ≥ tm−1|X) > 0.
Hence (11) holds if and only if fj(X) = 0 with probability 1 for all j. Denoting α =
(c1, · · · , cm−1, α¯′)′, then we can write
α′
∂`(1)(θ)
∂θ
∣∣∣∣
θ=θ0
=
{
m−1∑
s=1
cs
∂`(1)(θ)
∂γs
+ α¯′
∂`(1)(θ)
∂β
}
θ=θ0
=
m−1∑
s=1
cs
{
−
m∑
j=s+1
∆j +
∆se
−h0s
1− e−h0s
}
h0s
+ α¯′
m∑
j=1
∆j
{
−
j−1∑
k=1
h0kXk +
h0je
−h0j
1− e−h0j
Xj
}
.
Therefore the coefficient of ∆1 is f1(X) = (c1+ α¯
′X1)h01e
−h01/(1− e−h01). By setting f1(X) to
be 0, we obtain c1+ α¯
′X1 = 0 with probability 1. Since Var(X1) > 0, this implies α¯ = 0 and
then it follows that c1 = 0. Now f2(X) becomes f2(X) = c2h
0
2e
−h02/(1 − e−h02), so we have
c2 = 0. By continuing this procedure we conclude that c3 = · · · = cm−1 = 0. Therefore, we
obtain α = 0, which contradicts the assumption of nonzero α. This shows that I(θ0) must
be nonsingular. Then by Lemma 2 and the consistency of θˆn that we have already shown,
we obtain
√
n(θˆn − θ0) = I−1(θ0) 1√
n
n∑
i=1
wi
∂`i(θ)
∂θ
∣∣∣∣
θ=θ0
+ oP (1),
and asymptotic normality is guaranteed by the central limit theorem since wi{∂`i(θ)/∂θ} is
bounded and thus square integrable.
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Table 1: Summary statistics of simulations, with true parameter values β1 = 1 and β2 = −1.
n = 500. Mean sample size of completely observed subjects in the case-cohort sample is 200, in
which the mean number of censored subjects selected in the subcohort is 100.
Coverage Average Empirical Relative efficiency
Method Parameter Bias Percentage SD SD (from empirical variances)
Weighted β1 -0.024 0.931 0.270 0.290 0.607
likelihood β2 0.027 0.924 0.115 0.129 0.613
Full data β1 -0.009 0.937 0.204 0.226 1
MLE β2 0.008 0.932 0.093 0.101 1
Naive β1 0.247 0.706 0.195 0.221 –
estimator β2 -0.138 0.605 0.087 0.103 –
Pseudo β1 0.023 0.910 0.262 0.293 –
likelihood β2 -0.104 0.803 0.131 0.146 –
Multiple β1 0.035 0.956 0.353 0.294 –
imputation β2 -0.014 0.948 0.145 0.148 –
n = 3000. Mean sample size of completely observed subjects in the case-cohort sample is 400, in
which the mean number of censored subjects selected in the subcohort is 250.
Weighted β1 -0.006 0.941 0.217 0.222 0.519
likelihood β2 0.013 0.928 0.099 0.108 0.482
Full data β1 -0.004 0.948 0.153 0.160 1
MLE β2 0.001 0.948 0.066 0.075 1
Naive β1 0.307 0.441 0.146 0.156 –
estimator β2 -0.200 0.128 0.061 0.067 –
Pseudo β1 0.014 0.896 0.203 0.234 –
likelihood β2 -0.090 0.816 0.102 0.118 –
Multiple β1 -0.042 0.966 0.247 0.225 –
imputation β2 -0.002 0.929 0.120 0.128 –
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Table 2: Biases for estimation of the γi’s in the simulations.
n=500 (γi ≡ −2.41) n=3000 (γi ≡ −3.95)
γˆ1 γˆ2 γˆ3 γˆ4 γˆ5 γˆ1 γˆ2 γˆ3 γˆ4 γˆ5
Weighted likelihood 0.01 -0.01 -0.02 -0.00 -0.02 -0.01 -0.01 -0.00 -0.00 -0.01
Full data MLE -0.02 -0.01 -0.03 -0.03 -0.02 -0.01 -0.00 -0.01 -0.00 -0.00
Naive estimator 0.57 0.64 0.72 0.85 1.04 1.55 1.63 1.76 1.93 2.11
Pseudo likelihood 0.53 0.29 0.30 0.24 0.31 1.60 1.23 1.28 1.28 1.28
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Table 3: Estimated log relative hazards (RHs) of HIV infection in the vaccine trial.
(Antibody)1/5 White Sex Medium risk score High risk score
log(RH) -1.556 -0.105 -1.411 1.265 1.143
95% CI (-2.351, -0.757) (-0.655, 0.445) (-3.581, 0.759) (0.741, 1.789) (0.569, 1.717)
P value 0.001 0.708 0.202 0.000 0.000
White: 1 for white, 0 for nonwhite
Sex: 1 for female, 0 for male
Medium risk group: risk score is equal to 2 or 3
High risk group: risk score is greater than 3
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